Business Description
Mega Lifesciences PCL
ISIN : TH4984010009
Compare
Compare
Traded in other countries / regions
MEGA.Thailand IPO Date
2013-11-19Description
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.77 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.1 | |||||
| Interest Coverage | 92.93 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.26 | |||||
| Beneish M-Score | -2.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.6 | |||||
| 3-Year EBITDA Growth Rate | 9.7 | |||||
| 3-Year EPS without NRI Growth Rate | 23.3 | |||||
| 3-Year FCF Growth Rate | 5.9 | |||||
| 3-Year Book Growth Rate | 10.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 4.84 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.41 | |||||
| 9-Day RSI | 43.26 | |||||
| 14-Day RSI | 44.99 | |||||
| 6-1 Month Momentum % | -9.94 | |||||
| 12-1 Month Momentum % | -3.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.25 | |||||
| Quick Ratio | 1.49 | |||||
| Cash Ratio | 0.61 | |||||
| Days Inventory | 164.55 | |||||
| Days Sales Outstanding | 75.79 | |||||
| Days Payable | 104.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.9 | |||||
| Dividend Payout Ratio | 0.56 | |||||
| 3-Year Dividend Growth Rate | 28.9 | |||||
| Forward Dividend Yield % | 3.9 | |||||
| 5-Year Yield-on-Cost % | 10.58 | |||||
| Shareholder Yield % | 4.07 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.25 | |||||
| Operating Margin % | 18.52 | |||||
| Net Margin % | 12.71 | |||||
| FCF Margin % | 10.41 | |||||
| ROE % | 21.97 | |||||
| ROA % | 13.67 | |||||
| ROIC % | 36.18 | |||||
| ROC (Joel Greenblatt) % | 48.53 | |||||
| ROCE % | 24.35 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.96 | |||||
| PE Ratio without NRI | 13.92 | |||||
| Shiller PE Ratio | 23.65 | |||||
| Price-to-Owner-Earnings | 20.75 | |||||
| PEG Ratio | 0.99 | |||||
| PS Ratio | 2.28 | |||||
| PB Ratio | 3.84 | |||||
| Price-to-Tangible-Book | 4.48 | |||||
| Price-to-Free-Cash-Flow | 21.93 | |||||
| Price-to-Operating-Cash-Flow | 18.57 | |||||
| EV-to-EBIT | 14.52 | |||||
| EV-to-Forward-EBIT | 10.54 | |||||
| EV-to-EBITDA | 12.9 | |||||
| EV-to-Forward-EBITDA | 9.58 | |||||
| EV-to-Revenue | 2.12 | |||||
| EV-to-Forward-Revenue | 1.76 | |||||
| EV-to-FCF | 20.25 | |||||
| Price-to-Projected-FCF | 1.35 | |||||
| Price-to-DCF (Earnings Based) | 0.57 | |||||
| Price-to-DCF (FCF Based) | 0.7 | |||||
| Price-to-Median-PS-Value | 0.89 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.88 | |||||
| Price-to-Graham-Number | 1.66 | |||||
| Price-to-Net-Current-Asset-Value | 6.9 | |||||
| Earnings Yield (Greenblatt) % | 6.88 | |||||
| FCF Yield % | 4.57 | |||||
| Forward Rate of Return (Yacktman) % | 20.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mega Lifesciences PCL Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ฿) | 15,681.172 | ||
| EPS (TTM) (฿) | 2.283 | ||
| Beta | 0.75 | ||
| Volatility % | 21.5 | ||
| 14-Day RSI | 44.99 | ||
| 14-Day ATR (฿) | 0.56671 | ||
| 20-Day SMA (฿) | 41.5625 | ||
| 12-1 Month Momentum % | -3.55 | ||
| 52-Week Range (฿) | 34.75 - 46.75 | ||
| Shares Outstanding (Mil) | 871.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mega Lifesciences PCL Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mega Lifesciences PCL Stock Events
| Event | Date | Price(฿) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mega Lifesciences PCL Frequently Asked Questions
What is Mega Lifesciences PCL(BKK:MEGA)'s stock price today?
The current price of BKK:MEGA is ฿41.00. The 52 week high of BKK:MEGA is ฿46.75 and 52 week low is ฿34.75.
When is next earnings date of Mega Lifesciences PCL(BKK:MEGA)?
The next earnings date of Mega Lifesciences PCL(BKK:MEGA) is .
Does Mega Lifesciences PCL(BKK:MEGA) pay dividends? If so, how much?
The Dividend Yield %  of Mega Lifesciences PCL(BKK:MEGA) is 3.9% (As of Today), Highest Dividend Payout Ratio of Mega Lifesciences PCL(BKK:MEGA) was 0.61. The lowest was 0.4. And the median was 0.51. The  Forward Dividend Yield % of Mega Lifesciences PCL(BKK:MEGA) is 3.9%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers